EyePoint Pharmaceuticals, Inc.

NasdaqGM:EYPT Lagerbericht

Marktkapitalisierung: US$821.9m

EyePoint Pharmaceuticals Management

Management Kriterienprüfungen 2/4

EyePoint Pharmaceuticals CEO ist Jay Duker , ernannt in Jan 2023, hat eine Amtszeit von 1.83 Jahren. Die jährliche Gesamtvergütung beträgt $2.92M , bestehend aus 21.1% Gehalt und 78.9% Boni, einschließlich Aktien und Optionen des Unternehmens. besitzt direkt 0.091% der Aktien des Unternehmens, im Wert von $751.01K . Die durchschnittliche Betriebszugehörigkeit des Managementteams und des Verwaltungsrats beträgt 1.8 Jahre bzw. 3.3 Jahre.

Wichtige Informationen

Jay Duker

Geschäftsführender

US$2.9m

Gesamtvergütung

Prozentsatz des Geschäftsführergehalts21.1%
Amtszeit als Geschäftsführer1.8yrs
Eigentum des Geschäftsführers0.09%
Durchschnittliche Amtszeit des Managements1.8yrs
Durchschnittliche Amtszeit der Vorstandsmitglieder3.3yrs

Jüngste Management Updates

Recent updates

Revenues Not Telling The Story For EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) After Shares Rise 52%

Oct 29
Revenues Not Telling The Story For EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) After Shares Rise 52%

EyePoint Pharmaceuticals, Inc.'s (NASDAQ:EYPT) Intrinsic Value Is Potentially 38% Above Its Share Price

Sep 13
EyePoint Pharmaceuticals, Inc.'s (NASDAQ:EYPT) Intrinsic Value Is Potentially 38% Above Its Share Price

EyePoint Pharmaceuticals - After A Tough 2024 To Date, Is It Time To 'Buy The Dip' (Rating Upgrade)

Aug 29

These Analysts Think EyePoint Pharmaceuticals, Inc.'s (NASDAQ:EYPT) Sales Are Under Threat

Aug 15
These Analysts Think EyePoint Pharmaceuticals, Inc.'s (NASDAQ:EYPT) Sales Are Under Threat

EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Just Reported Second-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?

Aug 09
EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Just Reported Second-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?

Some Confidence Is Lacking In EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) As Shares Slide 27%

Jun 19
Some Confidence Is Lacking In EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) As Shares Slide 27%

EyePoint's Setback In NPDR Does Not Bode Well For DME (Rating Downgrade)

May 06

More Unpleasant Surprises Could Be In Store For EyePoint Pharmaceuticals, Inc.'s (NASDAQ:EYPT) Shares After Tumbling 26%

Mar 31
More Unpleasant Surprises Could Be In Store For EyePoint Pharmaceuticals, Inc.'s (NASDAQ:EYPT) Shares After Tumbling 26%

EyePoint Pharmaceuticals: Innovating Eye Treatment, Yet A 'Hold' At This Time

Feb 20

Subdued Growth No Barrier To EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) With Shares Advancing 41%

Feb 05
Subdued Growth No Barrier To EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) With Shares Advancing 41%

Is EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Trading At A 28% Discount?

Jan 29
Is EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Trading At A 28% Discount?

Optimistic Investors Push EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Shares Up 194% But Growth Is Lacking

Dec 18
Optimistic Investors Push EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Shares Up 194% But Growth Is Lacking

These Analysts Think EyePoint Pharmaceuticals, Inc.'s (NASDAQ:EYPT) Sales Are Under Threat

Dec 13
These Analysts Think EyePoint Pharmaceuticals, Inc.'s (NASDAQ:EYPT) Sales Are Under Threat

Calculating The Fair Value Of EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT)

May 14
Calculating The Fair Value Of EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT)

Optimistic Investors Push EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Shares Up 84% But Growth Is Lacking

Apr 17
Optimistic Investors Push EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Shares Up 84% But Growth Is Lacking

EyePoint Pharmaceuticals: Key Player In The Long-Acting Wet AMD Space

Aug 30

Health Check: How Prudently Does EyePoint Pharmaceuticals (NASDAQ:EYPT) Use Debt?

Jul 16
Health Check: How Prudently Does EyePoint Pharmaceuticals (NASDAQ:EYPT) Use Debt?

EyePoint Pharma announces 12-month phase 1 data for its treatment for eye disorder wAMD

Jul 15

Health Check: How Prudently Does EyePoint Pharmaceuticals (NASDAQ:EYPT) Use Debt?

Mar 06
Health Check: How Prudently Does EyePoint Pharmaceuticals (NASDAQ:EYPT) Use Debt?

EyePoint Pharmaceuticals (NASDAQ:EYPT) Is Using Debt Safely

Sep 24
EyePoint Pharmaceuticals (NASDAQ:EYPT) Is Using Debt Safely

Analyse der Geschäftsführervergütung

Wie hat sich die Vergütung von Jay Duker im Vergleich zu den Einnahmen von EyePoint Pharmaceuticals verändert?
DatumGesamtvergütungGehaltUnternehmensgewinne
Jun 30 2024n/an/a

-US$87m

Mar 31 2024n/an/a

-US$79m

Dec 31 2023US$3mUS$614k

-US$71m

Sep 30 2023n/an/a

-US$100m

Jun 30 2023n/an/a

-US$106m

Mar 31 2023n/an/a

-US$102m

Dec 31 2022US$2mUS$515k

-US$102m

Sep 30 2022n/an/a

-US$78m

Jun 30 2022n/an/a

-US$77m

Mar 31 2022n/an/a

-US$67m

Dec 31 2021US$3mUS$269k

-US$58m

Sep 30 2021n/an/a

-US$54m

Jun 30 2021n/an/a

-US$42m

Mar 31 2021n/an/a

-US$44m

Dec 31 2020US$53kn/a

-US$45m

Sep 30 2020n/an/a

-US$40m

Jun 30 2020n/an/a

-US$52m

Mar 31 2020n/an/a

-US$51m

Dec 31 2019US$80kn/a

-US$57m

Sep 30 2019n/an/a

-US$58m

Jun 30 2019n/an/a

-US$75m

Mar 31 2019n/an/a

-US$98m

Dec 31 2018US$27kn/a

-US$86m

Vergütung im Vergleich zum Markt: JayDie Gesamtvergütung ($USD2.92M) liegt im Durchschnitt der Unternehmen ähnlicher Größe auf dem Markt US ($USD3.23M).

Entschädigung vs. Einkommen: JayDie Bezüge der Mitarbeiter sind gestiegen, während das Unternehmen unrentabel ist.

Geschäftsführer

Jay Duker (65 yo)

1.8yrs

Amtszeit

US$2,915,146

Vergütung

Dr. Jay S. Duker, M.D., co-founded Hemera Biosciences Inc. and serves as its Executive Director. He serves as Member of Retina Segment Scientific Advisory Board at Aldeyra Therapeutics, Inc. He served as C...

Führungsteam

NamePositionAmtszeitVergütungEigentümerschaft
Jay Duker
President1.8yrsUS$2.92m0.091%
$ 751.0k
George Elston
Executive VP & CFO5yrsUS$1.78m0.072%
$ 589.1k
John Landis
Interim Head of R&D and Directorless than a yearUS$161.67k0.017%
$ 141.5k
Michael Maciocio
Senior Vice President of Manufacturing & Operations1.3yrskeine Datenkeine Daten
Ron Honig
Chief Legal Officer & Company Secretary6yrskeine Datenkeine Daten
Jennifer Leonard
Chief People Officer & Senior VP of IT5.8yrskeine Datenkeine Daten
David Jones
Senior VP & Chief Commercial Officer5.4yrsUS$1.46m0%
$ 0
Michael Pine
Chief Business Officer1.1yrsUS$1.61m0.021%
$ 169.5k
Isabelle Lefebvre
Chief Regulatory Officer2.7yrskeine Datenkeine Daten
Marcia Sellos-Moura
Senior VP and Head of Development & Program Management1.3yrskeine Datenkeine Daten
Ramiro Ribeiro
Chief Medical Officerless than a yearkeine Datenkeine Daten
Anna Kluczewska
CEO of AION Diagnostics Ltdno dataUS$225.94kkeine Daten

1.8yrs

Durchschnittliche Betriebszugehörigkeit

58yo

Durchschnittliches Alter

Erfahrenes Management: EYPTDas Führungsteam des Unternehmens gilt nicht als erfahren ( 1.8 Jahre durchschnittliche Betriebszugehörigkeit), was auf ein neues Team schließen lässt.

Vorstandsmitglieder

NamePositionAmtszeitVergütungEigentümerschaft
Jay Duker
President1.3yrsUS$2.92m0.091%
$ 751.0k
John Landis
Interim Head of R&D and Director6.1yrsUS$161.67k0.017%
$ 141.5k
Anna Kluczewska
CEO of AION Diagnostics Ltdno dataUS$225.94kkeine Daten
Goran Ando
Independent Non-Executive Chairman6.4yrsUS$214.78k0.020%
$ 163.2k
Wendy DiCicco
Independent Director5.3yrsUS$171.67k0.015%
$ 123.7k
Nancy Lurker
Vice Chair8.2yrsUS$3.74m0.34%
$ 2.8m
Carl Regillo
Co- Chairman of Scientific Advisory Board3.3yrskeine Datenkeine Daten
Glenn Jaffe
Member of Executive Scientific Advisory Board3.3yrskeine Datenkeine Daten
Karen Zaderej
Independent Director2.3yrsUS$149.17k0.025%
$ 204.7k
Charles Wykoff
Co-Chair of Scientific Advisory Board3.3yrskeine Datenkeine Daten
Rishi Singh
Member of Executive Scientific Advisory Board3.3yrskeine Datenkeine Daten
Sophie Bakri
Member of Executive Scientific Advisory Board3.3yrskeine Datenkeine Daten

3.3yrs

Durchschnittliche Betriebszugehörigkeit

66yo

Durchschnittliches Alter

Erfahrener Vorstand: EYPTDie Vorstandsmitglieder gelten als erfahren (3.3 Jahre durchschnittliche Amtszeit).